10 Best Biotech Stocks to Buy Under $10
The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC's "Squawk Box" on July 25 to discuss various topics, including the current status of the biotech industry and what to expect...
Recursion Pharmaceuticals Inc. (RXRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 32,988,631 | $166,922,471 | -6% | 1.22% |
| 2. | MIC Capital Partners Mubadala Investment | 9,644,032 | $48,798,807 | 9.58% | |
| 3. | 1,715,562 | $8,680,744 | +362% | 0% | |
| 4. | 1,448,800 | $7,330,928 | +1938% | 0.01% | |
| 5. | Citadel Investment Group Ken Griffin | 1,314,552 | $6,651,633 | -51% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.82 | 66,822 | $522,354.26 | 12,985,927 | 2023-03-02 | Filing | |
| $7.94 | 48,867 | $388,082.17 | 12,919,105 | 2023-03-01 | Filing | |
| $7.97 | 815 | $6,495.55 | 12,870,238 | 2023-02-28 | Filing | |
| $7.69 | 52,500 | $403,725.00 | 12,869,423 | 2023-02-27 | Filing | |
| $7.64 | 109,118 | $833,552.40 | 12,816,923 | 2023-02-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.52 | 36,599 | $202,172.88 | 668,197 | 2025-08-18 | Filing | |
| $5.28 | 17,875 | $94,380.00 | 0 | 2025-08-11 | Filing | |
| $5.28 | 100,000 | $528,000.00 | 0 | 2025-08-11 | Filing | |
| $5.28 | 500,300 | $2,641,584.00 | 1,004,619 | 2025-08-11 | Filing | |
| $6.04 | 138,574 | $836,986.96 | 1,117,450 | 2025-03-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 36,071,178 | $182,520,161 | 0% | |
| 2. | 28,371,063 | $143,557,577 | 0% | |
| 3. | 24,173,815 | $122,319,504 | 0.09% | |
| 4. | 14,667,491 | $74,217,504 | 0.3% | |
| 5. | 13,434,171 | $67,976,906 | 100% |
News See All
10 Best Penny Stocks to Buy for the Next 5 Years
Yahoo Finance Markets Reporter Josh Schafer joined “Asking for a Trend” with Josh Lipton to discuss important points from the trading session on August 21, Thursday.
Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares
In separate regulatory filings on Tuesday, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that its chief executive officer (CEO), chief financial officer (CFO), and chief research and development...
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid
Recursion Pharmaceuticals, Inc.
12 Best Healthcare Stocks to Buy Under $30
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there are any opportunities ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025Recursion Pharmaceuticals, Inc. misses on earnings expectations.
Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings
Recursion Pharmaceuticals grew its share prices for a fourth straight day on Monday, adding 9.59 percent to close at $6.40 apiece as investors repositioned portfolios ahead of its second quarter earnings...
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts.
10 Best Small Cap AI Stocks to Buy According to Analysts
On July 14, Wedbush's Dan Ives appeared on CNBC to discuss the expected tech sector earnings and explained how he thinks AI will give a boost to more than just the hyperscalers.
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.
Billionaire Hedge Funds
